APLM
Apollomics Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.05
+4.49%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$21.86
From 52W high−39.84%
Volume5451.00
Market cap$64.27M
P/E (TTM)—
P/S (TTM)7.6x
Div yield—
Key dataOct 19, 2026
Open
$21.86
From 52W high
−39.84%
Volume
5451.00
Market cap
$64.27M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.6x
P/E (TTM)
—
RSI (14)
47.2
MomentumView details →
1D Return
+4.49%
YTD Return
+17.80%
SummaryUpdated Dec 1, 2025
Apollomics, Inc. (NASDAQ:APLM) is a clinical-stage biotechnology company founded in 2015 and headquartered in Foster City, California. Originally incorporated as CBT Pharmaceuticals, Inc., the company changed its name to Apollomics in January 2019 and completed its transition to a publicly traded company on NASDAQ in March 2023. The company operates research and development facilities across California, China (Hangzhou and Shanghai), and Australia, focusing on the discovery and development of innovative oncology therapies to address significant unmet medical needs in cancer treatment.
Similar companies
Latest newsMore news →
Apollomics Inc. CFO Peter Kuan-How Lin purchased 26,667 Class A ordinary shares at $15.0 per share, totaling $400,005, on August 14, 2026, as part of a private placement.63d agoApollomics Inc. announced a private placement of securities to accredited investors for approximately $10 million, expected to close on August 14, 2026.69d agoApollomics Inc. received notice from Nasdaq that it regained compliance with the Market Value of Listed Securities requirement for continued listing on the Nasdaq Capital Market.98d ago